Evidence map›Paper›PMID 29147035›Full record

ArticleCanadian journal of chemistry2017

Dendrimers for Ocular Drug Delivery.

Michael G Lancina, Hu Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian journal of chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Overview of Recent Advances in Nano-Based Ocular Drug Delivery.International journal of molecular sciences · 2023
    Review
  9. Review
  10. Review
  11. Light-responsive biomaterials for ocular drug delivery.Drug delivery and translational research · 2023
    Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Michael G LancinaDepartment of Biomedical Engineering, Virginia Commonwealth University, Richmond, VA 23284, United States.
Hu YangDepartment of Chemical & Life Science Engineering, Virginia Commonwealth University, Richmond, VA 23219, United States.

Funding

Hybrid Nanoparticles for GlaucomaR01EY024072 · NEI · VIRGINIA COMMONWEALTH UNIVERSITY · PI KOMPELLA, UDAY B, YANG, HU · 2014 to 2016
$1.3M
NEI NIH HHS R01 EY024072
6 · The paper itself

Abstract

Existing methods of administering ocular drugs are limited in either their safety or efficiency. Nanomedicine therapies have the potential to address this deficiency by creating vehicles that can control drug biodistribution. Dendrimers are synthetic polymeric nanoparticles with a unique highly organized branching structure. In recent years, promising results using dendrimer vehicles to deliver ocular drugs through different routes of administration have been reported. In this review, we briefly summarize these results with emphasis on the dendrimer modifications used to target different ocular structures.

Indexed as

dendrimernanomedicineocular drug delivery

Identifiers

PMID29147035
PMCPMC5683719

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.